References
1. Javanian M, Bayani M, Shokri M, Sadeghi-Haddad-Zavareh M, Babazadeh
A, Yeganeh B, et al. Clinical and laboratory findings from patients with
COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study.
Rom J Intern Med. 2020;58(3):161-7.
2. Javanian M, Bayani M, Shokri M, Sadeghi-Haddad-Zavareh M, Babazadeh
A, Ghadimi R, et al. Risk factors for mortality of 557 adult patients
with COVID 19 in Babol, Northern Iran: a retrospective cohort study.
Bratisl Lek Listy. 2021;122(1):34-8.
3. Javanian M, Masrour-roudsari J, Bayani M, Ebrahimpour S. Coronavirus
disease 2019 (COVID-19): What we need to know. Caspian Journal of
Internal Medicine. 2020;11(2):235-6.
4. Boyton RJ, Altmann DM. Risk of SARS-CoV-2 reinfection after natural
infection. The Lancet. 2021;397(10280):1161-3.
5. Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling M-J, et
al. Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce
Risk of Reinfection. medRxiv. 2021.
6. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al.
BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting.
New England Journal of Medicine. 2021;384(15):1412-23.
7. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al.
Persistence and decay of human antibody responses to the receptor
binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci
Immunol. 2020;5(52).
8. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et
al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for
months. Science. 2020;370(6521):1227-30.
9. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med.
2021;384(5):403-16.
10. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S,
et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl
J Med. 2020;383(27):2603-15.
11. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al.
Immunological memory to SARS-CoV-2 assessed for up to 8 months after
infection. Science. 2021;371(6529).
12. Huang WC, Huang LM, Chang IS, Tsai FY, Chang LY. Varicella
breakthrough infection and vaccine effectiveness in Taiwan. Vaccine.
2011;29(15):2756-60.
13. Adebanjo TA, Pondo T, Yankey D, Hill HA, Gierke R, Apostol M, et al.
Pneumococcal conjugate vaccine breakthrough infections: 2001–2016.
Pediatrics. 2020;145(3).
14. Tyagi K, Ghosh A, Nair D, Dutta K, Singh Bhandari P, Ahmed Ansari I,
et al. Breakthrough COVID19 infections after vaccinations in healthcare
and other workers in a chronic care medical facility in New Delhi,
India. Diabetes Metab Syndr. 2021;15(3):1007-8.
15. Munoz FM, Cramer JP, Dekker CL, Dudley MZ, Graham BS, Gurwith M, et
al. Vaccine-associated enhanced disease: Case definition and guidelines
for data collection, analysis, and presentation of immunization safety
data. Vaccine. 2021;39(22):3053-66.
16. Kellam P, Barclay W. The dynamics of humoral immune responses
following SARS-CoV-2 infection and the potential for reinfection. The
Journal of general virology. 2020;101(8):791.
17. Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene
M, et al. Durability of Responses after SARS-CoV-2 mRNA-1273
Vaccination. N Engl J Med. 2021;384(1):80-2.
18. Giannitsarou C, Kissler S, Toxvaerd F. Waning Immunity and the
Second Wave: Some Projections for SARS-CoV-2. Bennett Institute for
Public Policy: University of Cambridge; 2020 June.
19. Zilla ML, Keetch C, Mitchell G, McBreen J, Shurin MR, Wheeler SE.
SARS-CoV-2 serologic immune response in exogenously immunosuppressed
patients. The journal of applied laboratory medicine. 2021;6(2):486-90.
20. Heeger PS, Larsen CP, Segev DL. Implications of defective immune
responses in SARS-CoV-2 vaccinated organ transplant recipients. Sci
Immunol. 2021;6(61).
21. Geisen UM, Berner DK, Tran F, Sumbul M, Vullriede L, Ciripoi M, et
al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in
patients with chronic inflammatory conditions and immunosuppressive
therapy in a monocentric cohort. Ann Rheum Dis. 2021.
22. McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ.
Comparative systematic review and meta-analysis of reactogenicity,
immunogenicity and efficacy of vaccines against SARS-CoV-2. npj
Vaccines. 2021;6(1):1-14.
23. Keehner J, Horton LE, Pfeffer MA, Longhurst CA, Schooley RT, Currier
JS, et al. SARS-CoV-2 infection after vaccination in health care workers
in California. New England Journal of Medicine. 2021;384(18):1774-5.
24. Jacobson KB, Pinsky BA, Montez Rath ME, Wang H, Miller JA, Skhiri M,
et al. Post-vaccination SARS-CoV-2 infections and incidence of
presumptive B. 1.427/B. 1.429 variant among healthcare personnel at a
northern California academic medical center. Clinical Infectious
Diseases. 2021.
25. England PH. Annex A: report to JCVI on estimated efficacy of a
single dose of Pfizer BioNTech (BNT162b2 mRNA) vaccine and of a single
dose of ChAdOx1 vaccine (AZD1222). 2020.
26. Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, et al.
Evidence for increased breakthrough rates of SARS-CoV-2 variants of
concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021:1-6.
27. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta
K-D, et al. Impact of vaccination on new SARS-CoV-2 infections in the
UK. medRxiv. 2021.
28. Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, et
al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and
vaccine-induced sera. Cell. 2021;184(9):2348-61 e6.
29. Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, et
al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J
Med. 2021;384(23):2212-8.
30. Conti P, Caraffa A, Gallenga C, Kritas S, Frydas I, Younes A, et al.
The British variant of the new coronavirus-19 (Sars-Cov-2) should not
create a vaccine problem. J Biol Regul Homeost Agents. 2021;35(1):1-4.
31. McEwen AE, Cohen S, Bryson-Cahn C, Liu C, Pergam SA, Lynch J, et al.
Variants of concern are overrepresented among post-vaccination
breakthrough infections of SARS-CoV-2 in Washington State. medRxiv.
2021.
32. Bouton TC, Lodi S, Turcinovic J, Weber SE, Quinn E, Korn C, et al.
COVID-19 vaccine impact on rates of SARS-CoV-2 cases and post
vaccination strain sequences among healthcare workers at an urban
academic medical center: a prospective cohort study. medRxiv. 2021.
33. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al.
COVID-19 vaccine coverage in healthcare workers in England and
effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a
prospective, multicentre, cohort study. Lancet. 2021;397(10286):1725-35.
34. Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber
L, et al. Decreased SARS-CoV-2 viral load following vaccination.
MedRxiv. 2021.
35. Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, et al.
Association between vaccination with BNT162b2 and incidence of
symptomatic and asymptomatic SARS-CoV-2 infections among health care
workers. JAMA. 2021.
36. Bleier BS, Ramanathan Jr M, Lane AP. COVID-19 vaccines may not
prevent nasal SARS-CoV-2 infection and asymptomatic transmission.
Otolaryngology–Head and Neck Surgery. 2021;164(2):305-7.
37. Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber
L, et al. Initial report of decreased SARS-CoV-2 viral load after
inoculation with the BNT162b2 vaccine. Nat Med. 2021;27(5):790-2.
38. Mor V, Gutman R, Yang X, White EM, McConeghy KW, Feifer RA, et al.
Short-term impact of nursing home SARS-CoV-2 vaccinations on new
infections, hospitalizations, and deaths. J Am Geriatr Soc. 2021.
39. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et
al. Post-vaccination SARS-CoV-2 infection: risk factors and illness
profile in a prospective, observational community-based case-control
study. medRxiv. 2021.
40. Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, et
al. Antibody responses to the BNT162b2 mRNA vaccine in individuals
previously infected with SARS-CoV-2. Nat Med. 2021;27(6):981-4.
41. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate
reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine
recipients. The Lancet. 2021;397(10277):875-7.
42. Alene M, Yismaw L, Assemie MA, Ketema DB, Gietaneh W, Birhan TY.
Serial interval and incubation period of COVID-19: a systematic review
and meta-analysis. BMC Infectious Diseases. 2021;21(1):1-9.
43. Qin J, You C, Lin Q, Hu T, Yu S, Zhou X-H. Estimation of incubation
period distribution of COVID-19 using disease onset forward time: a
novel cross-sectional and forward follow-up study. Science advances.
2020;6(33):eabc1202.
44. Rao SN, Manissero D, Steele VR, Pareja J. A narrative systematic
review of the clinical utility of cycle threshold values in the context
of COVID-19. Infectious diseases and therapy. 2020:1-14.
45. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 vaccines. Jama.
2021;325(13):1318-20.
46. Jęśkowiak I, Wiatrak B, Grosman-Dziewiszek P, Szeląg A. The
Incidence and Severity of Post-Vaccination Reactions after Vaccination
against COVID-19. Vaccines. 2021;9(5):502.
47. Al-Maqbali JS, Al Rasbi S, Kashoub MS, Al Hinaai AM, Farhan H, Al
Rawahi B, et al. A 59-Year-Old Woman with Extensive Deep Vein Thrombosis
and Pulmonary Thromboembolism 7 Days Following a First Dose of the
Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine. American Journal of Case
Reports. 2021;22.
48. Sara Oliver M. Overview of data to inform recommendations for
booster doses of COVID-19 vaccines. 2021.
49. Cohen JI, Burbelo PD. Reinfection with SARS-CoV-2: implications for
vaccines. Clinical Infectious Diseases. 2020.
50. Chirumbolo S. Vaccination hesitancy and the “myth” on mRNA-based
vaccines in Italy in the COVID-19 era: Does urgency meet major safety
criteria? Journal of Medical Virology. 2021;93(7):4049-53.
51. Saied SM, Saied EM, Kabbash IA, Abdo SAE-F. Vaccine hesitancy:
Beliefs and barriers associated with COVID-19 vaccination among Egyptian
medical students. Journal of Medical Virology. 2021;93(7):4280-91.
52. Biswas N, Mustapha T, Khubchandani J, Price JH. The Nature and
Extent of COVID-19 Vaccination Hesitancy in Healthcare Workers. Journal
of Community Health. 2021.
53. Ali Z, Sarwar M, Ansar S, Awan UA, Ahmed H, Aftab N, et al. COVID-19
vaccination hesitancy in patients with autoimmune diseases: A mystery
that needs an immediate solution! Journal of medical virology.
2021;93(9):5216-8.
54. Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb
FJ. COVID-19 Vaccination Hesitancy in the United States: A Rapid
National Assessment. Journal of Community Health. 2021;46(2):270-7.
55. Razai MS, Chaudhry UAR, Doerholt K, Bauld L, Majeed A. Covid-19
vaccination hesitancy. BMJ. 2021;373:n1138.